logo

UBX’s Stock Market Puzzle: Piecing Together 2023’s Performance

OPEN Stock

A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The index has shown a price gain of 82.30% this year. Over the last six months, there has been a weaker performance of 33.83%. The price of UBX fallen by 58.93% during the last 30 days period. For the last 5-days stocks have improved 78.18%.

Unity Biotechnology Inc ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $2.02 on 02/16/24, while the lowest value for the same period was recorded at $0.94 on 12/31/24.

52-week price history of UBX Stock

Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Unity Biotechnology Inc’s current trading price is -11.88% away from its 52-week high, while its distance from the 52-week low is 89.42%. The stock’s price range during this period has varied between$0.94 and $2.02. The Unity Biotechnology Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.57 million for the day, a figure considerably higher than their average daily volume of 85540.0 over last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Unity Biotechnology Inc (UBX) has experienced a quarterly rise of 21.92% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 33.68M and boasts a workforce of 19 employees.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 1.3293, with a change in price of +0.3100. Similarly, Unity Biotechnology Inc recorded 84,267 in trading volume during the last 100 days, posting a change of +21.09%.

UBX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for UBX stands at 1.73. Similarly, the long-term debt-to-equity ratio is also 1.46.

UBX Stock Stochastic Average

As of today, Unity Biotechnology Inc’s raw stochastic average for the last 50 days stands at 81.56%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 81.56%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 79.25% and 55.65%, respectively.

Most Popular